Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3

BACKGROUND: In the double-blind, phase 3 PALOMA-2 and PALOMA-3 studies, palbociclib plus endocrine therapy (ET) demonstrated significant improvement in progression-free survival versus placebo plus ET in patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Breast Cancer
Glavni autori: Masuda, Norikazu, Mukai, Hirofumi, Inoue, Kenichi, Rai, Yoshiaki, Ohno, Shinji, Ohtani, Shoichiro, Shimizu, Chikako, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Iwata, Hiroji, Toi, Masakazu
Format: Artigo
Jezik:Inglês
Izdano: Springer Singapore 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7925474/
https://ncbi.nlm.nih.gov/pubmed/33085032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-020-01162-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items